Cargando…

Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin

OBJECTIVE: In this study we aimed to investigate the efficacy and safety of dapagliflozin addition to diabetic patients using high dose insulin. METHODS: The current study was carried out in the outpatient diabetic clinics of Fatih Sultan Mehmet Education and Research Hospital. Thirty diabetic patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sertbas, Meltem, Sertbas, Yasar, Okuroglu, Nalan, Akyildiz, Ali Burkan, Sancak, Seda, Ozdemir, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500813/ https://www.ncbi.nlm.nih.gov/pubmed/31086522 http://dx.doi.org/10.12669/pjms.35.2.21

Ejemplares similares

The relationship between thyroid antibody titer and levothyroxine dose in patients with overt primary hypothyroidism
por: Okuroglu, Nalan, et al.
Publicado: (2017)

Treatment of Chronic Hepatitis C Can Improve Glycemic Control in Patients with Type 2 Diabetes
por: Okuroglu, Nalan, et al.
Publicado: (2018)

Mean platelet volume changes before and after glycated hemoglobin (HbA(1c)) improvement in a large study population
por: Sertbas, Yasar, et al.
Publicado: (2016)

The Effect of Glucose Variability on QTc Duration and Dispersion in Patients with Type 2 Diabetes Mellitus
por: Sertbas, Yasar, et al.
Publicado: (2017)

Current situation analysis of diabetic home care patients
por: Sertbas, Meltem, et al.
Publicado: (2019)

Relationship between Metabolic Syndrome Components and COVID-19 Disease Severity in Hospitalized Patients: A Pilot Study
por: Erman, Hande, et al.
Publicado: (2022)

Association of blood groups on the risk of COVID-19 infection, morbidity, and mortality
por: Sertbas, Meltem, et al.
Publicado: (2021)

The association between QT interval changes and the treatment protocols of COVID-19 patients
por: Sertbas, Yasar, et al.
Publicado: (2022)

Genome-Scale Metabolic Modeling for Unraveling Molecular Mechanisms of High Threat Pathogens
por: Sertbas, Mustafa, et al.
Publicado: (2020)

The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
por: Huang, Ying, et al.
Publicado: (2022)

An Efficient Big Data Anonymization Algorithm Based on Chaos and Perturbation Techniques †
por: Eyupoglu, Can, et al.
Publicado: (2018)

Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic network
por: Sertbaş, Mustafa, et al.
Publicado: (2014)

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
por: Wilding, John P.H., et al.
Publicado: (2009)

Personal, social, and environmental correlates of physical activity and sport participation in an adolescent Turkish population
por: Timurtaş, Eren, et al.
Publicado: (2022)

Cervical spine giant cell bone tumor: a case report
por: Sertbaş, İdris, et al.
Publicado: (2019)

Inflammatory Markers in Patients Using Domiciliary Non-invasive Mechanical Ventilation: C Reactive Protein, Procalcitonin, Neutrophil Lymphocyte Ratio
por: Ocakli, Birsen, et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2023)

Clinical outcomes of COVID-19 in patients with chronic diseases
por: Sertbas, Yasar, et al.
Publicado: (2023)

Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic “Overlap” severe asthma: Biological agent preference in atopic-eosinophilic severe asthma
por: Tepetam, Fatma Merve, et al.
Publicado: (2023)

A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes
por: Li, Yinhui, et al.
Publicado: (2022)

Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience
por: Scorsone, Alessandro, et al.
Publicado: (2018)

Insulin dose reduction in dapagliflozin combination therapy for type 1 diabetes mellitus: the RISING-STAR study
por: Hamaguchi, Masahide, et al.
Publicado: (2022)

Brain Inspired Cortical Coding Method for Fast Clustering and Codebook Generation
por: Yucel, Meric, et al.
Publicado: (2022)

Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
por: Yang, Ai-Yu, et al.
Publicado: (2020)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
por: Vart, Priya, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
por: Tamez, Hector E., et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16‐week double‐blind treatment period
por: Araki, Eiichi, et al.
Publicado: (2016)

Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study
por: Araki, Eiichi, et al.
Publicado: (2021)

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
por: Taberner-Cortés, Alida, et al.
Publicado: (2020)

Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes
por: SAYED, Noha, et al.
Publicado: (2020)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

Where are we in patient safety in the ED in Turkey?
por: Aksu, Nalan M., et al.
Publicado: (2019)

Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
por: Ishihara, Hisamitsu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_92s7ge822cq8rdn8atto8ispfv